SINGAPORE, December 20, 2025 /PRNewswire/ — Gene Solutions, a pioneering genetic testing company, announced its key achievements at the European Society for Medical Oncology (ESMO) Asian Congress 2025, held in Singapore from December 5-7. Highlights included a comprehensive symposium, seven scientific abstracts with two Best Poster designations, and significant engagement with thousands of oncologists from across the Asia-Pacific region at the company’s exhibition stand.
2025 marked a year of substantial progress for Gene Solutions, with an expanded presence and partnerships in India, Turkey and Taiwan. regionHong Kong DASAnd Continent China. The company has advanced precision oncology through The first multi-cancer early detection in Asia (MCED) in a large prospective study involving 9,024 participants (published in BMC Medicine). In parallel, tumor DNA circulating in the real world (cDNA) on molecular residual disease (MRD) involving 623 patients (published in JCO Oncology Advances, ASCO Publications) demonstrated high accuracy for early detection of relapses compared to imaging, enabling more rapid interventions.
Symposium Highlights: AI-Powered Liquid Biopsy and Multi-Omics Across the Cancer Care Continuum
Chaired by Professor Herbert Ho Fung Loong (Chinese University of Hong Kong, Hong Kong SAR) and Professor Nick Pavlakis (University of Sydney, Australia), the symposium — “AI-powered liquid biopsy and multi-omics in action: closing the genomic knowledge gap in the Asia-Pacific region”– attracted a sold-out audience. It presented actionable clinical evidence covering early detection, treatment selection and post-treatment monitoring.
Faculty included Asst. Professor Aaron Tan Chia-Ken (National Cancer Center of Singapore, Singapore), Dr Le Son Tran and Dr Dang L. Nguyen (Institute of Medical Genetics, Vietnam) and Professor Aya El Helali (University of Hong Kong, Hong Kong SAR). Key themes covered:
- Large-Scale Early Detection (SPOT-MAS): A single 10 mL multi-omics blood test combining genetic, epigenetic and fragmentomic features through targeted deep and shallow genome-wide sequencing.
Trained on data from more than 20,000 cancer patients and 25,000 healthy controls, it integrates retrospective (K-DISCOVERY) and prospective (K-DETEK) cohorts of more than 11,000 asymptomatic people, with actual deployment to more than 30,000 people in six Asian countries. - Real-world performance of SPOT-MAS in 10 cancers: In a large real-world study of 12,281 individuals (median age 43 years) with enrichment for familial cancer risk (24.5%), the test demonstrated a sensitivity of 78.2%, a specificity of 99.8%, a positive predictive value (PPV) of 67%, a negative predictive value (NPV) of 99.9% and an accuracy in predicting the origin of the cancer. tumor. of 80.3%. These results were comparable to those previously reported in the K-DETEK prospective validation study (n = 9,024).
- Treatment Selection and Monitoring (K-TRACK ctDNA-MRD): Validated for colorectal, breast, lung, hepatocellular carcinoma (HCC), and gastric cancers to enable risk stratification and earlier intervention. Real-world Asian data indicate detection of ctDNA progression up to 14 months before imaging and identification of resistance mechanisms in metastatic settings.
- AI-Based Advanced Biomarkers (K-4CARE): The K-4CARE platform integrates DNA profiling (504 genes), transcriptomic profiling (19,435 genes), and longitudinal cDNA-MRD monitoring, to support accurate decision-making, including complex scenarios such as tissue-of-origin detection with 87.7% prediction accuracy in cancer of unknown primary (CUP) and improving fusion detection by 20%.
- ESMO Consensus: The recent ESMO Consensus (EBAI), published in November 2025, provides baseline requirements for AI-based biomarkers in oncology – including requirements for ground truth, performance, generalizability, fairness, and evidence to establish their robustness.
Selected faculty opinion:
“The challenge is balancing performance in early detection of multiple cancers with affordability. We achieve this through robust feature engineering, supervised machine learning, and high-quality multi-omics training datasets.” Said Dr. The Sound Tran.
“In early-stage cancer cases, cancers may still recur in some patients despite adjuvant therapy, while some patients may already be cured and do not need further adjuvant therapy. MRD testing has the potential to transform how we care for these patients by allowing clinicians to escalate or de-escalate treatment more appropriately.” added Assistant Professor Tan Chia-Ken Aaron.
“AI-based biomarkers will not replace molecular testing; they will amplify it, especially when tissue is limited” commented Professor Herbert Ho Fung Loong.
Scientific recognition: seven abstracts and two best posters
Gene Solutions presented seven posters covering MCED, tumor profiling, MRD, immunotherapy and population genetics. Two studies received the best poster prize:
Best Poster (229P) – Integrated cfRNA + ctDNA liquid biopsy for better early detection of colorectal cancer -Trang T. Tran
Best poster (183P) – Scalable platform to produce non-genetically engineered allogeneic NK cells and predict cytotoxicity in solid tumors —Thursday Dao
Additional summaries:
- 913P: Multimodal cfDNA test for early detection of lung cancer in patients with suspicious lung nodules — Ho D. Vo
- 11P: Spectrum of BRCA1/BRCA2 pathogenic variants in 14,529 Vietnamese women — Le Phuong Thuy
- 227P: Integrated genomic and immune profiling improves prediction of chemotherapy benefit in resectable colorectal cancer — Tran B. Nguyen
- 791P: Exploiting multi-omics data from tumor and plasma cDNA in advanced lung cancer — Phuc Nguyen
- 784P: Real-world performance of tumor-agnostic and informed hybrid cDNA assays predicting recurrence/progression in Southeast Asia — Van Anh H. Nguyen
Participation in the exhibition:
Live demonstrations and clinical discussions at the Gene Solutions exhibition stand brought together thousands of oncologists and researchers from across Asia, highlighting the need for accessible, high-precision genomic solutions to improve patient outcomes.
“Our presence at the ESMO Asia program highlighted regionally validated multi-omics solutions, from SPOT-MAS to K-TRACK and K-4CARE, as well as recognition of our scientific contributions through two Best Poster Awards,” said Dr. Sinh Nguyen, Medical Director of Oncology at Gene Solutions. “Looking ahead to 2026, we remain committed to improving access through cost optimization and strategic partnerships, enabling patients to further benefit from earlier detection, informed treatment decisions and real-time monitoring.
About Genetic Solutions
Gene Solutions is a global biotechnology company headquartered in Singapore with a mission to make advanced genomic solutions accessible and affordable. Leveraging multi-omics, next-generation sequencing (NGS) and artificial intelligence, the company offers a comprehensive portfolio, including next-generation prenatal screening for fetal and maternal health (triSure), early detection of multiple cancers (SPOT-MAS), and comprehensive tumor profiling and ctDNA monitoring (K-TRACK, K-4CARE).
Since 2017, Gene Solutions has performed more than three million genetic tests globally through CAP-accredited laboratories in multiple markets. Through continued innovation and strategic collaborations, the company advances early cancer detection, precision care and reproductive health globally.
For more information, visit www.genesolutions.com or contact pr@genesolutions.com
Important Disclaimer
The tests described may be offered as laboratory developed tests (LDTs) in CAP accredited laboratories; availability and regulatory status varies by country/jurisdiction. The results are for professional use only. Performance characteristics are study specific and may vary by population, setting, or sample quality. This press release contains forward-looking statements based on current expectations regarding study results, test performance, clinical utility, partnerships and potential benefits. Actual results may differ materially due to risks and uncertainties, including regulatory, clinical, market and competitive factors. Gene Solutions undertakes no obligation to update these statements.
View original content to download multimedia:^ https://www.prnewswire.com/apac/news-releases/gene-solutions-concludes-successful-esmo-asia-congress-2025-with-ai-powered-multi-omics-liquid-biopsy-symposium-and-two-best-poster-awards-302647419.html
SOURCE Gene Solutions Genomics Pte Ltd
